Peptides Explained

Follistatin can bind myostatin—one of the body's major restraints on skeletal-muscle growth. Animal studies are dramatic, and small human gene-therapy studies have produced encouraging signals in serious muscle disease.

But is a vial labeled "Follistatin-344" equivalent to the therapy used in those trials?

John Garrett explains FST288, FST315, and FST344; the myostatin/activin pathway; the difference between gene therapy and recombinant protein; the evidence for muscle size versus function; and the key safety and product-identity questions.

Follistatin is not an FDA-approved muscle-building medication. Educational content only; not medical advice.

Explore the free Peptides Explained app: https://app.peptidesexplained.info

Glutathione gets called the "master antioxidant," and the underlying biology really is important. But does that mean oral supplements, liposomal products or glutathione IVs deliver the sweeping detox, energy, immune and anti-aging benefits often attached to them?

John breaks down glutathione biology, the GSH/GSSG cycle, oral human data, NAC, skin-related research and the gap between changing a biomarker and changing a meaningful health outcome. The episode also covers the 2026 FDA warning and recalls involving compounded injectable glutathione and elevated endotoxin levels.

The key question: where does established biology end and wellness marketing begin?

Educational only. Not medical advice.

For more information on Research Peptides go to PeptidesExplained.info/OfflinePeptides

Is taking smaller GLP-1 doses multiple times per week actually "microdosing"? Not necessarily.

This episode separates split dosing from true dose reduction and explains the pharmacokinetic logic using semaglutide, tirzepatide, and retatrutide. John breaks down half-life, peaks, troughs, total exposure, and why changing the schedule does not automatically mean using less drug.

We also examine the major evidence gap: once-weekly dosing has a strong clinical foundation for semaglutide and tirzepatide, while retatrutide remains investigational — and direct randomized evidence showing routine split dosing is superior is not established.

Educational only. No individualized dosing protocols are provided.

Download The Peptide App at ThePeptide.App/Explained

For more information on research peptides check out PeptidesExplained.info/OfflinePeptides

A peptide…in a pill?

Icotyde, or icotrokinra, is an FDA-approved oral peptide designed to block the IL-23 receptor in moderate-to-severe plaque psoriasis. In Phase 3 trials, it produced substantial skin clearance and outperformed an established oral comparator on several key endpoints.

But the biggest story may be the delivery platform itself. Peptides usually struggle to survive the digestive tract and reach circulation. Icotyde shows what can happen when medicinal chemistry, structural engineering and extreme receptor potency come together.

This episode breaks down what worked, what the safety data show, and what this does—and does not—mean for the future of oral peptides.

Educational only. Not medical advice.

If BPC-157, TB-500, KPV, MOTS-C and similar peptides are so interesting, why don't we have giant randomized human trials?

This episode looks at the less dramatic—and more important—answer: clinical trials require a sponsor, regulatory strategy, manufacturing package, defined indication, safety program, and a very large amount of money. For old, easily copied, poorly protected, or commercially fragmented compounds, the incentive to fund definitive trials may be weak.

John also explains why that does not excuse the evidence gap. "No Phase 3 trial" is not proof that a peptide works. It simply means confidence should remain limited until better evidence exists.

Educational only. Not medical advice.

Download The Peptide App @ ThePeptide.App/Explained

For more info on research peptides visit PeptidesExplained.info/OfflinePeptides

John Garrett shares his N=1 experience with the so-called "Trinity Stack"—established TRT, retatrutide, and tesamorelin—combined with resistance training, Zone 2 cardio, high protein intake, creatine, sauna, and cold plunging.

The transformation was dramatic. But what likely came from appetite control? What helped preserve muscle? What might the GH/IGF-1 axis have added? And how much credit belongs to the boring fundamentals?

This is a candid personal testimony and accessible science breakdown—not a deep dive, a dosing guide, or a warning lecture. John also explains what happened during an eight-week break and why he recently restarted with a goal of reaching 10% body fat.

Educational only. Retatrutide remains investigational and is not FDA-approved.

SNAP-8 is a synthetic cosmetic octapeptide marketed for expression lines and frequently called "Botox in a bottle." John Garrett, RN, breaks down the SNAP-25 and SNARE-complex mechanism, the difference between topical SNAP-8 and injected botulinum toxin, the skin-penetration problem, the Argireline evidence, a small 2024 microneedle combination study, safety, and the limits of the current human data.

The mechanism is plausible. The evidence is not strong enough to call it a needle-free Botox equivalent.

Educational content only; not medical advice.

Visit peptidesexplained.info for more info and resources

For more info on research peptides check out PeptidesExplained.info/OfflinePeptides or email John at [email protected]

What exactly is GLP-1 microdosing?

Depending on who you ask, it can mean remaining on the starter dose, taking a fraction of that dose, spacing injections farther apart, stepping down after weight loss, or using a tiny amount for food noise and longevity.

Those are not the same strategy.

John Garrett breaks down the new low-dose semaglutide and tirzepatide data, FDA-approved dose structures, weight-regain research, maintenance questions, side effects, and the major gap between individualized clinical titration and social-media "microdosing" protocols.

Educational content only. Not medical advice.

Can a peptide reverse age-related immune decline?

Thymalin and Thymogen are often discussed together, but one is a complex calf-thymus extract and the other is the defined dipeptide Glu-Trp. John Garrett explains thymic involution, T-cell biology, proposed mechanisms, the Russian clinical history, limitations of the human evidence, safety, and U.S. regulatory status.

The science is interesting. The "immune rejuvenation" and life-extension claims remain unproven.

Educational only. Not medical advice.

Check out The Peptide App here: thepeptide.app/explained

What is Pinealon, and does this three-amino-acid peptide really protect the aging brain?

Pinealon—also called EDR or Glu-Asp-Arg—is a synthetic tripeptide associated with the Khavinson bioregulator research program. It is discussed for memory, neuroprotection, oxidative stress, brain aging, and even Alzheimer's disease, but the evidence is much more complicated than the marketing language suggests.

John Garrett, examines Pinealon's proposed mechanism, cell and animal research, a newer induced-neuron study, and the PubMed-indexed human reports that are often overlooked. The episode also explains why Pinealon is different from Epitalon, where the human evidence is weak, what remains unknown about brain exposure and long-term safety, and why a plausible mechanism is not the same thing as an established cognitive therapy.

Educational content only. Not medical advice.